When cost is not an issue, the ADA recommends choosing a second-line medication from one of the following: dipeptidyl peptidase-4 inhibitors (DPP4i), glucagon-like peptide-1 receptor agonists (GLP-1-RA), or sodium/glucose co-transporter inhibitors (SGLT2i) [3]
Healthline.com
Lingvay I, Sumithran P, le Roux CW, Cohen RV
The drugmaker also claims the medication can "reduce the risk of major adverse cardiovascular events (MACE) such as death, heart attack, or stroke in adults with overweight or obesity and established cardiovascular disease." How does it work
However, the pleiotropic nature of GLP1 might be subject to species variability as well as a dependence upon the source of GLP1 (i.e
Marques JG, Calado G, Martins P, Pinto PL